Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Pexelizumab: Phase III

Preliminary results from the double-blind, placebo-controlled U.S. Phase III PRIMO-CABG trial in 3,000 patients showed that pexelizumab missed the primary

Read the full 209 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE